ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma pneumoniae Community-acquired Pneumonia in Children.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06325293 (A Randomized Controlled Non-inferiority Trial of Placebo Versus Macrolide Antibiotics for Mycoplasma Pneumoniae Infection in Children With Community-acquired Pneumonia - the MYTHIC Study), which is not on this map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Non-inferiority Trial of Placebo Versus Macrolide Antibiotics for Mycoplasma Pneumoniae Infection in Children With Community-acquired Pneumonia - the MYTHIC Study
Who cites it
41 citing papers in PubMed, 64 citations in OpenAlex.
- Effects of propofol and sevoflurane on T-cell immune function and Th cell differentiation in children with SMPP undergoing fibreoptic bronchoscopy.Annals of medicine · 2022Trial
- Development of a scale for early prediction of refractory Mycoplasma pneumoniae pneumonia in hospitalized children.Scientific reports · 2021Trial
- Design of Ion-Pairing Azithromycin liposome for Local Pulmonary Delivery with Prolonged Lung Retention.AAPS PharmSciTech · 2026Article
- Impact of pathogen co-detection on disease severity and clinical outcomes in children with Mycoplasma pneumoniae pneumonia.World journal of pediatrics : WJP · 2026Article
- Machine learning-based prediction of severeTranslational pediatrics · 2026Article
- Taming the Inflammation: The Role of Corticosteroids in Pediatric Mycoplasma Pneumonia.Children (Basel, Switzerland) · 2026Review
- Effect of intravenous immunoglobulin combined with azithromycin sequential therapy on clinical outcomes and immune response in children withFrontiers in medicine · 2026Article
- Macrolide-resistantFrontiers in pediatrics · 2026Article
- Resurgence of Mycoplasma pneumoniae infections in children: emerging challenges and opportunities.Current opinion in infectious diseases · 2025Review
- Evolving clinical features of Mycoplasma pneumoniae infections following COVID-19 pandemic restrictions: a retrospective, comparative cohort study.European journal of pediatrics · 2025Article
- Association betweenTranslational pediatrics · 2025Article
- Volume ratio of pulmonary lesions as a novel indicator for predicting the occurrence of plastic bronchitis in children with Mycoplasma pneumoniae pneumonia.European journal of pediatrics · 2025Article
- Bronchoalveolar lavage cytokine profile and clinical features as risk predictors of plastic bronchitis in children with Mycoplasma pneumoniae pneumonia.Italian journal of pediatrics · 2025Article
- Differences in pulmonary microbiota of severe community-acquired pneumonia with different pathogenic microorganisms in children.BMC pediatrics · 2025Article
- Development and validation of an early diagnosis model for severe mycoplasma pneumonia in children based on interpretable machine learning.Respiratory research · 2025Article
- Antibiotic resistance and viral co-infection in children diagnosed with pneumonia caused by Mycoplasma pneumoniae admitted to Russian hospitals during October 2023-February 2024.BMC infectious diseases · 2025Article
- Model-based cost-impact analysis of a diagnostic test for patients with community-acquired pneumonia in Canada.BMC infectious diseases · 2025Article
- P1 adhesin genotype characteristics ofFrontiers in cellular and infection microbiology · 2025Article
- Article
- Review
Corrections and comments
- Commented on byReply to author.2021
- Commented on by
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are no reliable signs or symptoms that differentiate Mycoplasma pneumoniae (Mp) infection in community-acquired pneumonia (CAP) from other etiologies. Additionally, current diagnostic tests do not reliably distinguish between Mp infection and carriage. We previously determined that the measurement of Mp-specific immunoglobulin M antibody-secreting cells (ASCs) by enzyme-linked immunospot assay allowed for differentiation between infection and carriage. Using this new diagnostic test, we aimed to identify clinical and laboratory features associated with Mp infection.
methodsThis is a prospective cohort study of children, 3-18 years of age, with CAP from 2016 to 2017. Clinical features and biomarkers were compared between Mp-positive and -negative groups by Mann-Whitney U test or Fisher exact test, as appropriate. Area under the receiver operating characteristic curve (AUC) differences and optimal thresholds were determined by using the DeLong test and Youden J statistic, respectively.
resultsOf 63 CAP patients, 29 were Mp-positive (46%). Mp positivity was statistically associated with older age (median, 8.6 vs 4.7 years), no underlying disease, family with respiratory symptoms, prior antibiotic treatment, prolonged prodromal respiratory symptoms and fever, and extrapulmonary (skin) manifestations. Lower levels of C-reactive protein, white blood cell count, absolute neutrophil count, and procalcitonin (PCT), specifically PCT <0.25 μg/L, were statistically associated with Mp infection. A combination of age >5 years (AUC = 0.77), prodromal fever and respiratory symptoms >6 days (AUC = 0.79), and PCT <0.25 μg/L (AUC = 0.81) improved diagnostic performance (AUC = 0.90) (P = .05).
conclusionsA combination of clinical features and biomarkers may aid physicians in identifying patients at high risk for Mp CAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.